- Business05 December 2022
Adalvo signs licensing deal with MS Pharma for Solifenacin + Tamsulosin
Adalvo is pleased to announce that we have partnered with MS Pharma, signing a licensing deal for Solifenacin + Tamsulosin in the MENA region.
- Business02 December 2022
Riociguat Film Coated Tablets added to Adalvo product portfolio
Adalvo is pleased to announce the addition of Riociguat 0.5mg, 1mg, 1.5mg, 2mg & 2.5mg Film Coated Tabletsto our product Portfolio.
- Business29 November 2022
Adalvo successfully launches Enzalutamide in LATAM
Adalvo is pleased to announce the successful launch of Enzalutamide Soft Gel Capsule in LATAM, fulfilling our commitment to our partners, and strengthening our presence in select LATAM countries.
- Business25 November 2022
Adalvo and Aristo Pharma sign licensing & supply agreement to commercialise a basket of products
Adalvo is pleased to announce that it has entered into a partnership with Aristo Pharma, to commercialize several dermatology products. This licensing and supply agreement includes a basket of five products...
- Business24 November 2022
Adalvo announces successful DCP closure for Dimethyl Fumarate hard capsules
Adalvo is pleased to announce the successful DCP closure for Dimethyl Fumarate120 and 240mghard capsules, and several market authorizations have been granted already. This is an additional wave of DCP approvals, where we...
- Business21 November 2022
Dossier Readiness for Dalbavancin Injection planned by end 2022
As we strengthen our injection product pipeline, we are pleased to announce EU dossier readiness for Dalbavancin Injection will be complete by the end of 2022. We now proceed to dossier...
- Business18 November 2022
Obeticholic Acid Tablets added to Adalvo Portfolio
Adalvo is pleased to announce the addition of Obeticholic Acid Tablets to our product Portfolio, a niche orphan product with strong growth potential.
- Business17 November 2022
Adalvo offers an extensive portfolio of arthritis medications
We at Adalvo continue to strengthen our comprehensive arthritis medication portfolio, covering a unique selection for this indication. Arthritis is the swelling and tenderness of one or more joints. The...
- Business11 November 2022
Women Health Segment: Successful Pivotal BE Results
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. We offer an array of women’s health...
- Business19 October 2022
Edoxaban film coated tablets added to Adalvo product portfolio
Adalvo is pleased to announce the addition of Edoxaban film coated tablets to our product Portfolio. Dossier readiness for Edoxaban is expected in Q1 2024. Our product is being developed...
- Business11 October 2022
Adalvo starts its supplies with Onsolis® after successful completion of the acquisition
Following the successful completion of the acquisition of our first brand, Onsolis, we are pleased to announce that Adalvo will start supply of the product.
- Business07 October 2022
Adalvo announces successful MA approval for Solifenacin + Tamsulosin
Adalvo is delighted to announce the successful MA approval of Solifenacin + Tamsulosin in various EU markets.
- Achievements04 October 2022
Anil Okay is nominated as finalist for CEO of the year award
We are honored to have been recognized by CPhI Pharma, where our CEO, Anil Okay, has been nominated as a finalist for the CEO of the Year Award!
- Achievements30 September 2022
Adalvo nominated as finalist in five Global Generics & Biosimilars 2022 Awards
At Adalvo we are driven by our relentless passion and commitment to our partner network. We tirelessly strive for excellence in all of our endeavors, driven by a deep-rooted passion...
- Business29 September 2022
Adalvo and Actor Pharmaceuticals Sign Exclusive Licensing Agreement to Commercialise a Basket of Products in the Australian Market
Adalvo is pleased to announce that it has entered into a strategic partnership with an Australian based company, Actor Pharmaceuticals, to commercialize several pharmaceutical products within the Australian market.
- Business27 September 2022
Isavuconazole added to Adalvo Portfolio
Adalvo is pleased to announce the addition of Isavuconazole Oral and Injectable forms to our product Portfolio. Dossier readiness for these products is expected in Q1 2024.
- Business22 September 2022
Adalvo announces successful DCP approval for Teriflunomide 14 mg film-coated tablets
Adalvo is delighted to announce the successful DCP approval of our Teriflunomide 14 mg film-coated divisible tablets.
- Business20 September 2022
Fidaxomicin Film Coated Tablets added to Adalvo Product Portfolio
Adalvo is pleased to announce the addition of Fidaxomicin Film Coated Tablets, to our Product Portfolio within the antibiotic line. Our product is being developed in collaboration with one...
- Business15 September 2022
Women Health Segment: Progress on DCP Submission
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are pleased to...
- Business13 September 2022
Brivaracetam Film Coated Tablets added to Adalvo Portfolio
Adalvo is pleased to announce the addition of Brivaracetam film coated tablets, to our product Portfolio. We are currently working on dossier completion for this product, which is expected in...
- Business09 September 2022
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem...